about
Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.Diagnosis and treatment of recurrent laryngeal cancer following initial nonsurgical therapy.Combined P16 and human papillomavirus testing predicts head and neck cancer survival.A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancerThe BCL2-family of protein ligands as cancer drugs: the next generation of therapeutics.Lung cancer in HIV Infection.A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.Aerodigestive cancers in HIV infection.Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management.Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancerUpdate on primary head and neck mucosal melanoma.Cervical lymph node metastases from remote primary tumor sitesRisk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy.Current trends in initial management of oropharyngeal cancer: the declining use of open surgery.Human papillomavirus-associated head and neck squamous cell carcinoma survival: a comparison by tumor site and initial treatment.Postoperative strategies after primary surgery for squamous cell carcinoma of the head and neck.Chemotherapy regimens and treatment protocols for laryngeal cancer.Human papillomavirus infections in laryngeal cancer.Comorbidity in head and neck cancer: a critical appraisal and recommendations for practice.Contemporary management of lymph node metastases from an unknown primary to the neck: I. A review of diagnostic approaches.Distant metastases from head and neck squamous cell carcinoma. Part II. Diagnosis.Follow-up strategies in head and neck cancer other than upper aerodigestive tract squamous cell carcinoma.Recent trends in the management of minor salivary gland carcinoma.Causes of death of patients with laryngeal cancer.Salivary mucoepidermoid carcinoma revisited.Prevention of head and neck squamous cell carcinoma: removing the "chemo" from "chemoprevention".Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review.Adenoid cystic carcinoma of the head and neck--An update.The role of systemic therapy in the management of sinonasal cancer: A critical review.Palliative Reconstruction for the Management of Incurable Head and Neck Cancer.Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy.Continuous Activity Monitoring During Concurrent Chemoradiotherapy.Organ preservation with chemoradiation in advanced laryngeal cancer: The problem of generalizing results from randomized controlled trials.Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell linThe impact of transoral robotic surgery on the overall treatment of oropharyngeal cancer patients.Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors.Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond.When is reoperative surgery not indicated for recurrent head and neck squamous cell carcinoma?Exogenous expression of H-cadherin in CHO cells regulates contact inhibition of cell growth by inducing p21 expression.
P50
Q30252081-FB69042A-3F83-41AA-9561-A383FF1211E3Q33686288-DBC09C56-5446-4BB7-ACBA-A8B8FA5C70DDQ33870104-E151CEAE-9D13-41E0-9155-DFCCEF5F377EQ34156725-E97382E7-7AB4-428C-A771-5CBC5C7B0D63Q34194044-0618DC34-0FD6-43BD-BF96-AE4FF71093EFQ35137807-53AD0D3C-4604-457D-97BA-E3AB52768E3CQ35667193-9BA6C723-7558-4455-B78B-AF65985C1FAEQ35693308-1F0EF8A9-2E4E-4601-B14F-2DC47DB28C37Q36225612-8A43AA11-8975-438C-9E72-10DF68752DFEQ36246406-A81FDC34-5B2A-4488-B802-2731D6E4A3ACQ36301182-F08D5D27-E4D6-4B59-B0CB-2BDD2B38E8DDQ37178922-973E74DC-D128-4CD4-8815-C3ADB99714FAQ37190697-C0D0B095-2B64-4344-80FF-FB5915ED6640Q37416478-07CDA0B3-5A1C-4547-9C97-6B2FCE712EF1Q37623578-699A2C9D-AC0C-4254-A423-EF81EFC4E244Q37631295-568704DC-06B7-43CF-88A0-4CCDC67C117EQ37733145-BE75D1D9-732D-4AC3-9F11-7E182F0F7CFEQ37739426-EFF6C315-A556-42F9-AAB3-4A726634AED3Q37789678-82D84292-E153-466D-B3DF-3B8708B35B90Q37789927-901E2A4A-C79A-4D69-BCD1-BA3D313B4DEEQ37950284-EC2FEB13-0720-4A4C-A023-117A8250294FQ38004100-A2D3974F-38BD-4DD1-86F1-C13A6248291DQ38055702-A4F03009-1856-4EAF-9D6F-B804F56FA5E8Q38096338-D3DBA563-CF9E-43EC-8E73-54BC9930CC28Q38099551-EECFAB2D-1F4E-4AF9-B2CE-94474C5ED44AQ38207529-A989D657-720F-4888-B4FB-8AA4C9870653Q38272767-DF83DFD1-A3A8-4B46-B791-D66CC6C858E7Q38367277-46946BF6-1EE0-4C16-B576-32DA3532E8D0Q38460777-57BB3047-CBC3-4FB5-9FD8-63F87C3306D6Q38563054-3F6B305A-61A3-4124-B42E-88F41E687235Q38659116-BF8B38EC-48CE-4E90-AEDA-C822AA0C423BQ38672364-EE094B14-8AF5-4C79-A6FC-47E5E3C53E8DQ38884025-CF5D8180-91FF-48FB-AB64-8CFF9779FE2FQ38891530-E63C98F1-2EAF-48F0-AA8C-8BB43A01D8B0Q40141617-78D257AA-2920-4CFC-8A78-6E348AE1ECC5Q40966363-AAF0496B-0BED-4275-8802-115889BBBF6AQ42590228-CF64F066-2CC1-49A9-B2BF-E50FF54F51FEQ43234029-FD242A76-419B-4E0F-AF01-84C1D97F5852Q43793515-A6BFAF9B-C734-4986-A0BC-C0D3CF2F1340Q47617448-CCA9A702-F041-4BD3-8196-5F31D1093C22
P50
description
researcher ORCID ID = 0000-0002-3610-2266
@en
wetenschapper
@nl
name
Missak Haigentz
@ast
Missak Haigentz
@en
Missak Haigentz
@es
Missak Haigentz
@nl
type
label
Missak Haigentz
@ast
Missak Haigentz
@en
Missak Haigentz
@es
Missak Haigentz
@nl
prefLabel
Missak Haigentz
@ast
Missak Haigentz
@en
Missak Haigentz
@es
Missak Haigentz
@nl
P108
P31
P496
0000-0002-3610-2266